ABSTRACT
Selective estrogen receptor modulators (SERMS) are a new class of agents designed to select out the benefits of HRT on bone and the heart whilst avoiding the breast and uterine cancer risk.34 Tamoxifen was the first of the SERMS used in clinical practice. The only disadvantage with SERMS as a routine HRT is the absence of any beneficial effect on the menopausal vasomotor symptoms and the possibility of endometrial stimulation.36
